MDT

88.69

-0.03%↓

VEEV

282.61

+1.3%↑

A

120.6

-0.78%↓

WBA

11.54

+0.26%↑

HQY

98.77

-3.58%↓

MDT

88.69

-0.03%↓

VEEV

282.61

+1.3%↑

A

120.6

-0.78%↓

WBA

11.54

+0.26%↑

HQY

98.77

-3.58%↓

MDT

88.69

-0.03%↓

VEEV

282.61

+1.3%↑

A

120.6

-0.78%↓

WBA

11.54

+0.26%↑

HQY

98.77

-3.58%↓

MDT

88.69

-0.03%↓

VEEV

282.61

+1.3%↑

A

120.6

-0.78%↓

WBA

11.54

+0.26%↑

HQY

98.77

-3.58%↓

MDT

88.69

-0.03%↓

VEEV

282.61

+1.3%↑

A

120.6

-0.78%↓

WBA

11.54

+0.26%↑

HQY

98.77

-3.58%↓

Search

Crinetics Pharmaceuticals Inc

Cerrado

SectorSanidad

29.32 0.86

Resumen

Variación precio

24h

Actual

Mínimo

28.89

Máximo

29.55

Métricas clave

By Trading Economics

Ingresos

-16M

-97M

Ventas

361K

361K

Margen de beneficios

-26,807.202

Empleados

437

EBITDA

-17M

-110M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+165.83% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-369M

2.8B

Apertura anterior

28.46

Cierre anterior

29.32

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

162 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 jul 2025, 19:37 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

M3-Brigade Shares Fall on Merger With ReserveOne

8 jul 2025, 23:45 UTC

Charlas de Mercado

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

8 jul 2025, 23:27 UTC

Charlas de Mercado

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8 jul 2025, 23:27 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jul 2025, 23:21 UTC

Charlas de Mercado

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8 jul 2025, 23:21 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 jul 2025, 22:29 UTC

Adquisiciones, fusiones, absorciones

Capricorn to Pay A$1.5 Million in Cash and Shares

8 jul 2025, 22:28 UTC

Adquisiciones, fusiones, absorciones

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8 jul 2025, 21:58 UTC

Charlas de Mercado

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8 jul 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

8 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 jul 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 jul 2025, 19:53 UTC

Charlas de Mercado

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8 jul 2025, 19:53 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

8 jul 2025, 19:45 UTC

Charlas de Mercado

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8 jul 2025, 19:29 UTC

Charlas de Mercado

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8 jul 2025, 19:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

8 jul 2025, 19:11 UTC

Charlas de Mercado

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8 jul 2025, 19:01 UTC

Charlas de Mercado

Oil Futures Gain With Support From Products -- Market Talk

8 jul 2025, 18:49 UTC

Ganancias

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8 jul 2025, 18:41 UTC

Charlas de Mercado

Mexico's Inflation Seen Mixed in June -- Market Talk

8 jul 2025, 18:38 UTC

Charlas de Mercado

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8 jul 2025, 18:23 UTC

Charlas de Mercado

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8 jul 2025, 18:10 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

8 jul 2025, 18:10 UTC

Charlas de Mercado

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8 jul 2025, 17:24 UTC

Charlas de Mercado

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8 jul 2025, 17:06 UTC

Charlas de Mercado

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Crinetics Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

165.83% repunte

Estimación a 12 Meses

Media 77.25 USD  165.83%

Máximo 97 USD

Mínimo 60 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

9

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

30.39 / 33.46Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

162 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.